{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous Methylprednisolone\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To reduce acute inflammation and accelerate recovery from the relapse Presence of significant neurological deficits (visual acuity loss and gait disturbance)\n\n*   **Treatment:** Gastroprotection (e.g., Omeprazole)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Prophylaxis against gastric irritation and ulceration during high-dose steroid therapy\n\n*   **Treatment:** Physiotherapy and Occupational Therapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To assess fall risk and assist with mobility given the unsteady gait and spasticity\n\n*   **Treatment:** Disease Modifying Therapy (e.g., Ocrelizumab, Rituximab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Cannot initiate long-term immunotherapy until specific diagnosis (MS vs NMOSD vs MOGAD) is confirmed via MRI and antibody results\n\n\ntreatments = [{\"treatment\": \"Intravenous Methylprednisolone\", \"timing\": \"Start Now\", \"reasons\": [\"To reduce acute inflammation and accelerate recovery from the relapse\", \"Presence of significant neurological deficits (visual acuity loss and gait disturbance)\"]}, {\"treatment\": \"Gastroprotection (e.g., Omeprazole)\", \"timing\": \"Start Now\", \"reasons\": [\"Prophylaxis against gastric irritation and ulceration during high-dose steroid therapy\"]}, {\"treatment\": \"Physiotherapy and Occupational Therapy\", \"timing\": \"Start Now\", \"reasons\": [\"To assess fall risk and assist with mobility given the unsteady gait and spasticity\"]}, {\"treatment\": \"Disease Modifying Therapy (e.g., Ocrelizumab, Rituximab)\", \"timing\": \"Delay\", \"reasons\": [\"Cannot initiate long-term immunotherapy until specific diagnosis (MS vs NMOSD vs MOGAD) is confirmed via MRI and antibody results\"]}]"
}